Dec 13, 2022 / 04:00PM GMT
Simon Latimer - Ligand Pharmaceuticals Incorporated - Head of IR
Simon Latimer and I head Investor Relations at Ligand Pharmaceuticals and webcast. It's great to be back in person. Presenting today for Ligand will be Todd Davis, Chief Executive Officer; Matt Korenberg, President and Chief Operating Officer; Diane Retallack, Senior Vice President of Platform Technologies and Innovation; Andrew Reardon, Chief Legal Officer; Octavio Espinoza, Chief Financial Officer.
First, a few housekeeping items. Following the presentation, we will have a Q&A session, and we ask that you hold your questions until that time. Those joining by the webcast will have an opportunity to ask questions as well. We'll be using slides to guide our discussion today. We will also be using non-GAAP financial measures and some of our statements will be forward-looking.
Additional information regarding the risk factors and other matters concerning Ligand can be found in our summary press release issued earlier today, the slides associated with this event and our periodic filings with the SEC. Ligand undertakes no
Ligand Pharmaceuticals Inc Investor and Analyst Day Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers